<DOC>
	<DOCNO>NCT00048581</DOCNO>
	<brief_summary>The purpose clinical research study determine whether abatacept treatment background Disease Modifying Antirheumatic Drugs ( DMARDs ) relieve symptom rheumatoid arthritis ( RA ) participant currently receive anti-tumor necrosis factor ( TNF ) therapy least 3 month respond take anti-TNF therapy last 3 month respond . The safety treatment abatacept also evaluate . This study also 4.5-year long-term extension begin 6 month start study .</brief_summary>
	<brief_title>Phase III Study BMS-188667 ( CTLA4Ig ) Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy Who Have Failed Anti-TNF Therapy Past .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Eligibility Criteria : Active rheumatoid arthritis currently fail antiTNF therapy fail antiTNF therapy past . Women pregnant breast feed Current symptom serious medical disease History cancer last 5 year nonmelanoma skin cancer Chronic serious infection Active TB require treatment last 5 year Herpes zoster last 2 month Any active viral infection include Human Immunodeficiency Virus ( HIV ) Serious side effect associate previous antiTNF therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>